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ABSTRACT
The major high-affinity thrombin receptor, proteinase activated receptor-1 
(PAR-1) is expressed at low levels by the normal epithelium but is upregulated in 
many types of cancer, including lung cancer. The thrombin-PAR-1 signalling axis 
contributes to the activation of latent TGFβ in response to tissue injury via an avβ6 
integrin-mediated mechanism. TGFβ is a pleiotropic cytokine that acts as a tumour 
suppressor in normal and dysplastic cells but switches into a tumour promoter in 
advanced tumours. In this study we demonstrate that TGFβ is a positive regulator 
of PAR-1 expression in A549 lung adenocarcinoma cells, which in turn increases the 
sensitivity of these cells to thrombin signalling. We further demonstrate that this 
effect is Smad3-, ERK1/2- and Sp1-dependent. We also show that TGFβ-mediated 
PAR-1 upregulation is accompanied by increased expression of integrin av and β6 
subunits. Finally, TGFβ pre-stimulation promotes increased migratory potential of 
A549 to thrombin. These data have important implications for our understanding 
of the interplay between coagulation and TGFβ signalling responses in lung cancer.
INTRODUCTION
Lung cancer is a global health problem with 1.5 
million people being diagnosed worldwide every year. 
This condition accounts for 18% of all deaths from cancer, 
which makes it the leading cause of cancer mortality [1]. 
Cancer patients have a sevenfold increased risk of venous 
thromboembolism [2] and cancer-related coagulopathy 
is associated with advanced malignancy and correlates 
positively with increased mortality rates [3]. Cancer cells 
constitutively express tissue factor [4], the main initiator of 
the extrinsic coagulation pathway, and the leaky nature of 
the tumour vasculature contributes to the accumulation of 
thrombin in the tumour microenvironment [5]. Thrombin 
exerts a plethora of cellular effects via the activation of 
proteinase activated receptor-1 (PAR-1). PAR-1 belongs to 
a family of four G-protein coupled receptors (PAR 1-4) that 
are activated via a unique mechanism involving proteolytic 
cleavage of the N-terminus. This results in the unmasking 
of a tethered ligand, which then binds intramolecularly 
to the receptor and initiates cell signalling via the 
phosphorylation of the associated G-protein complex 
[6]. PAR-1 forms stable complexes with Gαi/o, Gαq/11, and 
Gα12/13 and thereby links to multiple second messenger 
pathways and influences multiple cellular responses [7].
PAR-1 is expressed at low levels by the normal 
epithelium but is upregulated in many types of cancer, 
including lung [5], gastric [8], ovarian [9], prostate 
[10], melanoma [11], breast [12] and colon cancer [13]. 
PAR-1 and vascular endothelial growth factor (VEGF) 
overexpression in lung cancer has been associated with 
increased metastatic potential [14] and reduced three-
year survival in non-small cell lung cancer [15]. PAR-1 
signalling also regulates the expression and leads to the 
activation of other receptors that contribute to cancer 
progression. These include platelet-activating factor 
receptor (PAFR) that causes platelet mobilisation and 
promotes tumour metastases [16], as well as epidermal 
growth factor receptor (EGFR) which also promotes 
tumour invasion [17].
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PAR-1 has been strongly linked to the integrin 
mediated activation of latent TGFβ, a pleiotropic cytokine 
that is a tumour suppressor in normal and dysplastic cells 
but turns into a tumour promoter in advanced cancer 
cells [18]. This mode of activation is highly cell-type 
specific and is mediated via an αvβ6 integrin-dependent 
mechanism in epithelial cells [19, 20]; whereas in 
fibroblasts, this mode of activation is mediated via an 
αvβ5 integrin-dependent mechanism [21]. Both modes of 
activation are dependent on the mechanotransduction of 
cytoskeletal tension within the cell, which in concert with 
matrix interactions leads to a change in the conformation 
of the latent TGFβ complex and release of active TGFβ 
[19, 21–23].
Human tumours overproduce TGFβ, which can lead 
to the loss of epithelial markers, such as E-cadherin, and 
epithelial-to-mesenchymal transition (EMT), an event 
which has been linked to increased tumour cell survival, 
motility and invasiveness [24]. This is also associated 
with modulation of tumour cell-stroma interactions 
through regulation of integrin expression [25], increased 
production of the matricellular protein, connective tissue 
growth factor (CTGF) [26] and re-modelling of the 
extracellular matrix [27]. The αvβ6 integrin is upregulated 
in many cancer cells and targeting αvβ6 leads to reduced 
TGFβ activation and cancer cell proliferation [28].
The importance of PAR-1 in mediating TGFβ 
activation in vivo is gaining increasing recognition 
[19, 21] but the effect of TGFβ signalling on PAR-1 
expression remains largely unexplored. In this study we 
investigated the interaction between TGFβ signalling 
and PAR-1 expression and functional activity in A549 
lung adenocarcinoma cells. We show for the first time 
that TGFβ increases PAR-1 gene, protein and cell surface 
expression and that this in turn results in increased A549 
cell responsiveness to subsequent thrombin stimulation. 
These findings shed important light on the interplay 
between coagulation and TGFβ signalling responses and 
further provide a potential novel mechanistic model by 
which these pathways may interact to promote lung cancer 
progression.
RESULTS
TGFβ increases PAR-1 expression and renders 
A549 cells more responsive to thrombin 
stimulation
A549 cells express low levels of PAR-1 under 
baseline conditions. Exposure to TGFβ (1 ng/ml) leads to a 
time-dependent upregulation of F2R/PAR-1 mRNA levels 
from 8 hours onwards with a 4-fold maximal increase at 
16 hours (Figure 1A). By 16 hours of TGFβ exposure, 
PAR-1 protein levels are also increased and subsequent 
thrombin-mediated PAR-1 stimulation led to increased 
ERK phosphorylation at 10 minutes when compared to 
control cells (Figure 1B). This increase in PAR-1 protein 
levels occurs with no evidence of E-cadherin loss as 
determined by immunocytofluorescence at 24 hours 
(Figure 1C). These data suggest that the increase in PAR-
1 expression in response to TGFβ stimulation for 24 hours 
is not associated with EMT.
Consistent with low protein expression of PAR-1 in 
A549 cells at baseline, stimulating cells with thrombin and 
the PAR-1 activating peptide, TFLLR, produced a delayed 
and modest release of intracellular calcium as determined 
by monitoring changes in fluorescence following 
incubation with Fluo4-AM (Figure 2A and 2B). Pre-
stimulation with TGFβ significantly increased subsequent 
calcium responses to either thrombin or TFLLR 
(Figure 2C). These effects were inhibited when thrombin 
was rendered catalytically inert with hirudin, as well as 
in the presence of the small molecule PAR-1 antagonist, 
RWJ58259 (Figure 2D). Moreover, pre-treatment with 
TGFβ increased the functional responsiveness of A549 in 
an agonist concentration-dependent manner (Figure 2E). 
Under baseline conditions, A549 cells mount a small, 
albeit significant, increase in intracellular calcium release 
with increasing concentrations of thrombin. In contrast, 
pre-exposure to TGFβ resulted in a 4-fold increase in 
the magnitude of the calcium response. Taken together 
these data led us to conclude that TGFβ increases PAR-1 
expression and the subsequent magnitude of the calcium 
response to thrombin.
TGFβ regulation of PAR-1 expression is Smad3-, 
MEK- and SP1-dependent
We next examined the potential mechanism by 
which TGFβ mediates these effects in A549 cells. TGFβ 
signals via the formation of a heterotetrameric receptor 
complex composed of a TGFβ type 2 receptor dimer 
with an activin-like kinase (ALK) TGFβ type 1 receptor 
dimer; this in turn triggers the Smad signalling pathway 
by phosphorylating Smad2 and Smad3. In the current 
study, we show that the effect of TGFβ pre-treatment on 
subsequent thrombin-mediated calcium release in A549 
cells is inhibited in a concentration-dependent manner in 
the presence of the ALK5 receptor inhibitor, SB431542, 
(IC50 = 1.7 μM) (Figure 3A).
The role of Smad2 and Smad3 in TGFβ-mediated 
PAR-1 upregulation was subsequently investigated 
using small interfering RNA (siRNA). The silencing 
of Smad2 and Smad3 expression was validated at the 
mRNA (Figure 3B and 3C) and protein levels (Figure 3D 
and 3E). Although Smad2 knockdown was found to exert 
a small but significant inhibitory effect on the subsequent 
TGFβ-mediated increase in PAR-1-mediated intracellular 
calcium release at 48 hours at siRNA concentrations of 
10 nM and 30 nM, the intracellular calcium flux remained 
significantly elevated above the unstimulated control cells 
exposed to thrombin (Figure 3F). In contrast, silencing 
Oncotarget65473www.impactjournals.com/oncotarget
of Smad3 expression significantly reduced the TGFβ-
mediated increase in subsequent PAR-1-mediated signalling 
responses to thrombin in a concentration-dependent 
manner (Figure 3G). Examination of the kinetics of 
Smad3 phosphorylation in A549 cells revealed that Smad3 
phosphorylation increases from 30 minutes following TGFβ 
exposure onwards, peaking at 1 hour with a near 20-fold 
increase (p<0.001 versus control), before returning to 
control levels by 24 hours (Figure 3H). Taken together these 
data led us to conclude that TGFβ mediates the increase in 
PAR-1 expression and functional responses via an ALK5/
Smad3-dependent mechanism.
TGFβ signalling responses are often dependent on 
cross-talk with Smad-independent pathways, including 
ERK, SAPK/JNK, and p38 MAPK pathways. Our 
studies revealed that the MEK1/MEK2 inhibitor, UO126, 
inhibited the TGFβ-mediated increase in thrombin-
stimulated intracellular calcium flux in a concentration-
dependent manner with an IC50 of 0.35 μM (Figure 4A). 
In contrast, inhibition of JNK, p38 and Rho kinase did 
not affect TGFβ-mediated increase in PAR-1 expression 
and signalling (data not shown). We also confirmed 
that TGFβ signalling in A549 cells leads to ERK1/2 
phosphorylation, which peaks early at 10 minutes post-
stimulation (Figure 4B).
We next addressed the question of which 
transcription factor might be involved downstream of 
Smad3 and ERK signalling. We focused our studies on 
the potential role of specificity protein 1 (Sp1) since this 
transcription factor has been linked to increased F2R 
promoter region binding [11], is known to interact with 
Smad3 [29] and is also implicated in carcinogenesis [30]. 
Our studies revealed that mithramycin A and WP631, two 
inhibitors that specifically displace Sp1 from DNA, were 
highly effective at blocking the TGFβ-induced increase in 
PAR-1 mRNA levels (Figure 5A and 5B).
Figure 1: TGFβ induces the expression of PAR-1 in A549 lung adenocarcinoma cells. Panel A. Human lung adenocarcinoma 
A549 cells were exposed to TGFβ (1 ng/ml) and mRNA collected at indicated times over the course of 24 hours. PAR-1 expression 
was quantified by real-time qPCR. Each data point represents the mean +/- SEM of 3 replicate wells, statistically analysed by Two-way 
ANOVA, **p<0.01, ***p<0.001 in comparison to control. Panel B. Western blot analysis of PAR-1 protein expression and phosphorylated 
and total ERK 1/2 levels following exposure to TGFβ (1 ng/ml) for 16 hours and subsequent thrombin (10 nM) stimulation at indicated 
times. Representative immunoblots with quantitated ratios phosphorylated ERK/total ERK. The PAR-1 predicted molecular weight is 
47 kDa but it is detected in most mammalian cells as a broad high molecular weight species due to differential N-linked glycosylation (63). 
Panel C. Immunocytofluorescence visualisation of E-cadherin (green) and PAR-1 (red) following exposure to TGFβ (1 ng/ml) for 24 hours. 
DAPI was used to visualise the nuclei. The top panel shows images for control cells and lower panel show the staining of TGFβ-stimulated 
cells, x20 original magnification.
Oncotarget65474www.impactjournals.com/oncotarget
TGFβ increases integrin expression in A549
We next examined the potential functional 
consequences of TGFβ-induced PAR-1 expression. PAR-
1 activation has been strongly linked to the integrin-
mediated activation of TGFβ via the αvβ6 integrin in 
epithelial cells [19] and the αvβ5 integrin in fibroblasts 
[21]. Examination of these integrin subunit mRNA levels 
in A549 cells following stimulation with TGFβ revealed 
that the αv and β6 subunits were significantly upregulated 
from 6 and 4 hours onwards, respectively (Figure 6A and 
6B) and that both integrin subunits remained significantly 
elevated throughout the duration of the experiment 
(24 hours). Taken together these data demonstrate that 
TGFβ-induced upregulation of PAR-1 expression is 
accompanied by increased expression of the major integrin 
subunits involved in the activation of the latent form of 
this cytokine.
Figure 2: TGFβ-mediated PAR-1 upregulation enhances A549 lung adenocarcinoma cell responsiveness to thrombin 
signalling. Intracellular calcium release was monitored in A549 cells, pre-treated with TGFβ (1 ng/ml), in response to thrombin (30 nM) 
and PAR-1 activating peptide, TFLLR (P1 AP, 100 μM). Panel A. Representative traces for thrombin-mediated calcium flux; Panel B. P1 
AP TFLLR. Panel C. Analysis of intracellular calcium responses mediated by PAR-1 agonists. Panel D. Thrombin signalling was inhibited 
directly by pre-incubation with hirudin (150 nM) and by using a PAR-1 antagonist, RWJ58259 (3 μM) and calcium flux was analysed. 
Panel E. Concentration-response curve to thrombin in TGFβ-pre-treated (solid line) and control (dotted line) A549 lung adenocarcinoma 
cells. Each data point represents the mean +/- SEM of 3-4 replicate wells from at least two independent experiments. Two-way ANOVA was 
performed for statistical analysis, ***p<0.001 comparison between control and TGFβ-pre-treated cells; +++p<0.001 comparison between 
treatments.
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TGFβ increases A549 migratory potential via 
PAR-1
We further examined A549 cell motility in 
response to PAR-1 activation following TGFβ pre-
treatment. Identical scratch wounds were introduced 
in confluent A549 cell monolayers. Cell migration 
was monitored over 24 hours and reported as wound 
confluence and cell density (Figure 7A and 7B). We 
observed that TGFβ and thrombin independently 
increased the rate of cell migration in A549 cells when 
compared with untreated cells at 24 hours. Subsequently, 
cells exposed to TGFβ and then stimulated with 
thrombin showed the highest rate of migration in this 
model. Inhibition of PAR-1 signalling with RWJ58259 
abrogated this response. We further investigated 
the dynamics of this response by investigating the 
time-course of A549 migration in the wound assay 
(Figure 7C and 7D). Data collected at 6, 12 and 18 hours 
confirmed that cells exposed to TGFβ have a faster 
migration rate compared with control stimulated cells 
throughout the experiment. Furthermore, RWJ58259 
inhibited the thrombin-mediated migration at 12 and 
18-hour time points (p<0.01) while the TGFβ-thrombin-
RWJ58259 treated cells migrated at a rate which was 
similar to TGFβ alone stimulated cells. These data led 
us to conclude that the additive effect of these two 
independent pathways increases A549 motility.
Figure 3: TGFβ upregulates PAR-1 expression in A549 lung adenocarcinoma cells via an ALK5-Smad3-dependent 
mechanism. Panel A. Dose-inhibition curve in A549 cells exposed to TGFβ (1 ng/ml) with varying concentrations of TGFβ receptor 
(ALK5) inhibitor, SB431542, for 24 hours and then stimulated with thrombin. Panels B and C. Smad2 and Smad3 siRNA knockdown 
measured by mRNA (real-time qPCR, each data point represents the mean +/- SEM of 3 replicate wells; one-way ANOVA, *p<0.05, 
***p<0.001, relative to non-transfected control) and Panels D and E. Smad2 and Smad3 protein knockdown 48 hours post-transfection 
(Western blot, semi-quantitative densitometry analysis of the total protein of interest relative to the β-actin loading control, each data point 
represents the mean +/-SEM of 2 replicates as shown on the blots). Panels F and G. Intracellular calcium release was measured in A549 
cells treated with varying concentrations of Smad2 and Smad3 siRNA, respectively, for 48 hours prior to stimulation with TGFβ (1 ng/ml) 
for 24 hours. Cells were incubated with Fluo-4AM calcium binding dye for one hour before being exposed to thrombin (30 nM). Each data 
point represents the mean +/- SEM of 3-4 replicate wells; Two-way ANOVA, ***p<0.001 comparison of control and TGFβ pre-treated 
cells. Panel H. A549 cells were incubated with or without TGFβ (1 ng/ml) for up to 24 hours. Representative immunoblots of total and 
phosphorylated Smad3 and quantification of relative intensity of pSmad3 immunoreactive bands by densitometry. Data shown are mean ± 
SEM of 3 independent experiments and expressed as fold increase over control cells, analysed by one-way ANOVA, *p<0.05, ***p<0.001.
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DISCUSSION
The PAR receptors act as sensors of extracellular 
proteinase gradients and allow cells to react and respond 
to proteolytic changes within their microenvironments 
[12]. PAR-1, the prototypic member of the PAR family, has 
been identified as an oncogene and has been reported to 
promote cancer invasion and metastasis in the context of 
multiple cancers, including breast, colon, lung, pancreatic 
and prostate cancer as well as melanoma [14, 31–35]. 
Furthermore, PAR-1 expression levels positively correlate 
with the degree of cancer invasiveness [33]. TGFβ 
signalling similarly regulates a plethora of cell responses, 
including cell growth, differentiation, apoptosis, motility, 
invasion, ECM production, angiogenesis, and immune 
responses [36]. In the setting of cancer, TGFβ plays a 
dichotomous role in that it acts as a tumour suppressor in 
early tumorigenesis and as an oncogene in the later phases 
of tumour progression [37].
The aim of the present study was to explore the 
interplay between PAR-1 and TGFβ signalling responses 
in the context of lung cancer. Using A549 adenocarcinoma 
cells, we show for the first time that TGFβ increases the 
expression of PAR-1 and thereby leads to increased cellular 
responsiveness to thrombin. Thrombin is regarded as a 
key mediator in cancer growth and metastatic spread, 
via both the formation of fibrin and via its plethora of 
PAR-1 mediated cellular responses, including effects on 
DNA synthesis and cell proliferation, platelet activation, 
vascular permeability, cell migration, and induction of 
pro-angiogenic and pro-metastatic factors, such as VEGF 
(Reviewed in [38]).
The TGFβ receptors are constitutively expressed 
and form heterotetrameric TβRII-ALK5 ligand-
receptor complexes upon ligand binding. This leads 
to phosphorylation of specific serine and threonine 
residues and activation of canonical TGFβ signalling 
via the phosphorylation of Smad2 and Smad3 that, upon 
binding to co-factor Smad4, translocate to the nucleus 
and influence target gene expression. In the present 
study, using ALK5 small molecule inhibition and siRNA 
knockdown of Smad2 and Smad3, we demonstrate that 
the upregulation of PAR-1 expression is both ALK-5 
and Smad3-dependent in A549 adenocarcinoma cells. 
Interestingly, the TGFβ-Smad3 signalling pathway has 
previously been shown to promote cancer cell survival 
and metastasis [39].
TGFβ bound to TβRII-ALK5 complexes also leads 
to phosphorylation of tyrosine residues and the recruitment 
of adaptor molecules involved in the activation of MAPK 
kinase (ERK, JNK and p38) signalling [40]. TGFβ-
dependent ERK signalling has been linked to EMT in 
cancer cells [41] and genetic profiling of TGFβ-mediated 
EMT revealed that ERK participates in the regulation 
of the expression of cell-matrix adhesion and motility 
genes [42]. In the present study, we show that the 
TGFβ-mediated increase in PAR-1 functional responses 
(calcium signalling) is also MEK-dependent; with no role 
identified for JNK or p38 signalling. It has previously 
been reported that at least 48 hours of prolonged exposure 
to TGFβ is necessary for a complete loss of epithelial 
marker expression and evidence of mesenchymal marker 
expression in cancer cells [43]. PAR-1 expression is low 
in lung epithelial cells; whereas fibroblasts express PAR-1 
Figure 4: TGFβ-ERK1/2 signalling is also involved in regulation of PAR-1 expression in A549 cells. Panel A. Dose-
inhibition curve in A549 cells exposed to TGFβ (1 ng/ml) with varying concentrations of MEK1/2 inhibitor, UO126, for 24 hours and 
then stimulated with thrombin (30 nM). Each data point represents the mean +/- SEM of 3-4 replicate wells. Panel B. Representative 
immunoblot of ERK1/2 phosphorylation in A549 cells incubated with TGFβ (1 ng/ml) for up to 30 minutes with corresponding pERK/total 
ERK ratios derived from densitometry analysis.
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Figure 5: TGFβ-mediated PAR-1 upregulation is blocked by Sp1 inhibitors. A549 lung adenocarcinoma cells were incubated 
with or without TGFβ (1 ng/ml) for 24 hours and in the presence of the Sp1 inhibitors. Panel A. Mithramycin A (10 μM) for 8, 16 and 
24 hours, Panel B. WP631 for 16 hours at the concentration 150 nM and 300 nM. PAR-1 expression was quantified by real-time qPCR. 
Each data point represents the mean +/- SEM of 3 replicate wells, analysed by Two-way ANOVA, **p<0.01, ***p<0.001 in comparison 
to vehicle control.
Figure 6: TGFβ promotes αv and β6 integrin sub-unit gene expression. Panels A and B. A549 lung adenocarcinoma cells were 
incubated with or without TGFβ (1 ng/ml) for 24 hours. The mRNA was collected at indicated times in the course of 24 hours. Integrin 
subunits αv and β6 expression was quantified by real-time qPCR. Each data point represents the mean +/- SEM of 3 replicate wells, 
analysed by Two-way ANOVA, **p<0.01, ***p<0.001 in comparison to control.
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abundantly [44, 45]. In our study we note that the increase 
in PAR-1 expression in A549 cells occurs within 24 hours 
of TGFβ stimulation when E-cadherin is still highly 
expressed, indicating that acquisition of PAR-1 expression 
precedes the EMT process. Interestingly, gastric cancer 
cells [46] and A549 cells [47] have been shown to 
undergo thrombin-induced EMT via PAR-1 and ERK 1/2 
activation, albeit over longer period of time (72 hours). 
In our study, we show that increased PAR-1 expression 
following exposure to TGFβ is also associated with 
increased ERK phosphorylation in response to thrombin 
stimulation. Taken together our findings combined with 
existing data in the literature point to the possibility that 
the early TGFβ-mediated increase in PAR-1 expression 
and subsequent increased responsiveness to thrombin 
could be a part of the EMT process.
In terms of the transcriptional regulation of PAR-
1 expression, the transcription factors involved remain 
to be fully characterized but appear to be highly cell-
specific. Moreover, PAR-1 expression is differently 
regulated during homeostasis and in disease, and displays 
both cell- and tissue-specific variations. The F2R gene 
promoter has been characterised and presents, among 
many transcription factor binding elements, two AP-2-Sp1 
complexes at its proximal 3’ end. Overall, these complexes 
contain 3 AP-2 binding sites and 7 Sp1 binding sites 
[48]. In human melanoma cells, AP-2 has been shown to 
repress PAR-1 expression and compete with the positive 
regulator Sp1. The loss of AP-2 and predominant binding 
of Sp1 is linked to the overexpression of PAR-1 and the 
metastatic phenotype of these cells [49]. This evidence 
together with the reported observation that Smad3 can 
form transcriptional complexes with Sp1 to regulate gene 
expression [50], led us to focus our investigation on Sp1 
as a candidate transcription factor in mediating TGFβ-
induced PAR-1 upregulation in A549 adenocarcinoma 
cells. These studies revealed that the widely used Sp1 
inhibitor, mithramycin A, that binds to GC rich DNA 
Figure 7: The effect of TGFβ treatment on A549 lung adenocarcinoma cells migration. A549 cells were incubated with 
or without TGFβ (1 ng/ml) for 24 hours and pre-treated with PAR-1 inhibitor, RWJ58259 (3 μM) for 30 minutes. Homogenous scratch 
wounds were introduced using WoundMaker (Essen Bioscience, UK) and cells immediately stimulated with thrombin (10 nM). Wound 
closure was monitored for up to 24 hours and data analysed using Incucyte Zoom Live Cell Imaging System (Essen Bioscience, UK). 
Panel A. Difference in wound cell density and Panel B. Wound confluence at 24 hours. Panel C and D. Time-course of wound closure with 
data collected at 6, 12 and 18 hours with control and control + TGFβ denoted by dashed lines, thrombin and thrombin + TGFβ denoted by 
continuous lines and thrombin + RWJ58259 and thrombin + TGFβ + RWJ58259 denoted by dotted lines. Data are plotted as mean +/- SEM 
of n=5 replicate wells from 2 independent experiments; Two-way ANOVA, +p<0.05, ++p<0.01, +++p<0.001 in comparison to control, 
*p<0.05, **p<0.01, ***p<0.001 comparison between stimulations.
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sequences [51–56], completely blocked the TGFβ induced 
increase in PAR-1 mRNA levels. We further confirmed the 
role of Sp1 in TGFβ-mediated PAR-1 regulation by using 
a second Sp1 inhibitor, the bisintercalating anthracycline, 
WP631, which has high specificity and binding affinity 
for Sp1-DNA binding sites at concentrations within the 
nanomolar range [57, 58].
We next sought to determine whether TGFβ-
induced PAR-1 expression is accompanied by an increase 
in αvβ6 integrin expression. This integrin is expressed 
at low levels in normal epithelium but is known to be 
upregulated in response to tissue injury [19] and cancer 
[59]. Moreover, blocking ανβ6 integrin and TGFβ 
signalling has been shown to reduce tumour invasiveness 
[28]. In the present study we found that the increase in 
PAR-1 expression following TGFβ stimulation in A549 
cells is accompanied by a concomitant upregulation of αv 
and β6 integrin subunit expression. It is important to note 
that the upregulation of the expression of these three genes 
did not require PAR-1 activation so that the upregulation 
of integrin expression is TGFβ dependent but PAR-1-
independent. It is tempting to speculate that the interplay 
of this TGFβ-PAR-1 axis might potentially lead to a feed-
forward mechanism, which could drive the perpetuation 
of ανβ6-mediated TGFβ activation and signalling in the 
presence of uncontrolled coagulation.
Finally, in order to further investigate the functional 
consequences of increased PAR-1 expression in response 
to TGFβ exposure in A549 cells, we performed a cell 
motility assay and show that there was a significant, 
additive effect on cell migration when TGFβ–pre-treated 
cells were stimulated by thrombin. These additive effects 
were abolished in the presence of the PAR-1 inhibitor. 
Although there is existing evidence that PAR-1 and TGFβ 
independently promote cancer cell motility and migration 
[12, 18, 60], to the best of our knowledge, this represents 
the first report of a potential novel mechanism by which 
the TGFβ and PAR-1 signalling pathways may converge 
to promote cancer cell function.
Conclusion and therapeutic implications
In conclusion, our data show for the first time that 
TGFβ is a potent inducer of PAR-1 expression in lung 
adenocarcinoma cells. These effects are mediated via 
canonical TGFβ signalling with ALK5 and Smad3 acting 
in cooperation with an ERK-dependent mechanism and 
Sp1-dependent gene transcription. The upregulation of 
PAR-1 is accompanied by increased αv and β6 integrin 
subunit expression providing a potential mechanism 
for prolonged TGFβ activation in the pro-coagulant 
environment. These findings provide a scenario for 
the convergence of TGFβ and coagulation signalling 
to promote cancer cell function and migration. Future 
studies with an orally available, potent, PAR-1 antagonist 
(SCH530348/vorapaxar; trade name, Zontivity) which 
was recently approved by the U.S. Food and Drug 
Administration to reduce the risk of heart attacks 
and stroke in high-risk patients [61], as well as αvβ6 
integrin blocking agents, which are currently in clinical 
development [62], may offer therapeutic approaches for 
lung adenocarcinoma and potentially other cancers.
MATERIALS AND METHODS
Reagents and inhibitors
Commercially-available A549 cells were 
characterised and sourced from ATCC (LGC Standards, 
UK). Human α-thrombin was purchased from Enzyme 
Research Laboratories, UK. Transforming growth factor 
β-1 (TGFβ-1) was purchased from R&D Biosystems, 
UK. PAR-1 agonist peptide TFLLR-NH2 was purchased 
from Bachem AG, Switzerland. Hirudin was purchased 
from Sigma, UK. MEK inhibitor, UO126, and ALK5 
inhibitor, SB431542 were purchased from Calbiochem, 
UK. PAR-1 ATAP2 detection antibody was purchased 
from Santa Cruz Biotechnology, USA. Total Smad2 and 
Smad3, and phosphorylated Smad2 and Smad3, ERK and 
phosphorylation ERK antibodies were purchased from 
Cell Signalling Technologies, USA. PAR-1 inhibitor, 
RWJ58259, was synthesised in-house by the Department 
of Chemistry, UCL. Mithramycin A was purchased from 
VWR International, UK and WP631 was purchased from 
Insight Biotechnology, UK.
RT-PCR and real-time RT-PCR analysis
Total RNA from cell culture lysates was isolated 
with TRIzol reagent as per manufacturer’s protocol 
(Invitrogen, UK). Contaminating genomic DNA was 
removed using the Ambion DNAfree kit and cDNA 
was prepared by reverse-transcription (RT) using the 
qScript cDNA SuperMix® kit (Quanta Biosciences, 
USA) following the manufacturer’s instructions. Real 
time RT-PCR was conducted using the Platinum SYBR 
Green qPCR SuperMix UDG (Invitrogen, UK) with 
~1 ng of cDNA, and in-house designed forward and 
reverse primers (Table 1) each at a final concentration 
of 800 nM, on a Mastercycler EP Realplex (Eppendorf, 
Germany) at primer annealing temperature of 60°C. The 
GeNorm algorithm was applied to produce the optimal 
normalisation factor and two housekeeping genes, ATP 
synthase, H+ transporting, mitochondrial F1 complex, beta 
polypeptide (ATP5B) and beta-2-microglobulin (B2M), 
showed the highest reference target stability for human 
cells. Housekeeping primer, Smad2 and Smad3 primer 
mixes were purchased from PrimerDesign (Southampton, 
UK). To examine the quantitative differences in target 
mRNA expression in each sample, Cp values were 
determined from the linear region of the logarithmic 
amplification plot. The fold change was subsequently 
Oncotarget65480www.impactjournals.com/oncotarget
calculated using the standard 2-ΔΔCp approach. Statistical 
analysis was performed using the ΔCp values.
Transfection with siRNA
SMARTpool ONTARGETplus Human siRNA 
targeting Smad2 and Smad3 and the ONTARGETplus 
Nontargeting Pool (Thermo Scientific, UK) were 
reconstituted to 20 μM stock in RNA buffer. A range of 
siRNA concentrations (100 nM, 30 nM, 10 nM, 3 nM, 
1 nM) was tested to optimise the conditions and combined 
with Interferin transfection reagent (Polypus, UK) as 
per the manufacturer’s protocol. Following reverse 
transfection protocol, A549 cells were combined with 
the transfection mix and immediately seeded. Cells were 
then incubated for 48 hours, after which the medium was 
removed and the samples collected for mRNA and protein 
analysis or replaced with serum-free medium for another 
24 hours before cells were stimulated.
Western blot
Cells were seeded in 24-well plates and following 
appropriate treatment, cells were washed with cold PBS 
and lysed in 100 μl of phosphosafe extraction buffer 
(Merck Chemicals, UK) supplemented with a complete 
protease inhibitor cocktail. BCA assay was used to measure 
protein concentration as per the manufacturer’s protocol 
and the sample mixed with Laemmli buffer containing 
DTT. Following protein denaturation, the samples were 
loaded onto a pre-cast 4-12% polyacrylamide gel (Bolt 
Bis-Tris Plus gels, Novex, Life Technologies, UK). 
A Plus Prestained Protein Ladder (Fermentas, UK) with 
10-250 kDa detection range was run in a separate lane 
to identify the molecular weights of individual proteins. 
Electrophoresis was performed at 165 V for 35 minutes. 
Dry protein transfer onto polyvinyldene difluoride (PVDF) 
membrane was performed using the iBlot Gel Transfer 
Device (Novex, Life Technologies, UK) at 20 V for 
7 minutes. The membrane was subsequently incubated 
in blocking buffer, followed by primary detection 
antibodies for the protein of interest and finally with a 
specific horseradish peroxidise (HRP)-linked secondary 
antibody. The membrane was developed by enhanced 
chemiluminescence (ECL) following the manufacturer’s 
instructions (GE Healthcare, UK). Immunoreactive 
protein bands were visualised by exposing the membrane 
to autoradiography film developer (Kodak, UK) and the 
exposure time adjusted to the strength of the signal.
Intracellular calcium measurement
Cells were seeded 48 hours prior to the experiment 
in black 96-well plates with a clear bottom. On the day 
of the assay 1 vial of Fluo 4-AM dye was resuspended 
in 10 ml of HBSS/Hepes assay buffer without calcium or 
magnesium (Invitrogen, UK). Cells were incubated with 
the dye, 100 μl/well, for 30 minutes at 37°C and calibrated 
for another 30 minutes at room temperature. The PAR-1 
antagonists used in this study were added and incubated 
with the dye for an hour prior to the experiment. PAR-1 
agonists were prepared at 3x final desired concentration in 
assay buffer and 50 μl per well of appropriate compound 
was added to a 96-well agonist plate. Changes in the 
intracellular Ca2+ were monitored using a fluorescent 
image plate reader FLIPR Tetra (Molecular Devices, 
USA) and the results displayed and analysed using the 
ScreenWorks software. The device is fitted with a standard 
ECCM camera that records the fluorescent signal produced 
by light-emitting diodes (LED) that excites the Fluo-4AM 
dye at wavelength of 494 nm with emission at 516 nm. 
The fluorescence was monitored for 10 seconds before 
the agonists were simultaneously dispensed to the 96-well 
plate by the overhead pipettor. Readings were recorded 
every second for the first 60 seconds and every 6 seconds 
for the next 120 seconds. The change in intracellular 
calcium [Ca2+] was quantified as an increase in relative 
fluorescence units (RFUs). The difference between 
maximum and minimum RFU was used to plot the results.
Immunocytofluorescence
Cells were seeded in 8-well chamber slides (Fisher 
Scientific, UK) and cultured for 48 hours in a humidified 
atmosphere with 5% CO2 at 37°C. Serum-starvation was 
carried out for 24 hours. Cells were subsequently treated 
for another 24 hours, washed in PBS and fixed with 4% 
paraformaldehyde for 10 minutes at room temperature. 
Cells were subsequently permeabilised in 0.4% Triton-X 
for 10 minutes and blocked in 3% bovine serum albumin 
(BSA), 5% goat serum in PBS for 1 hour. Following three 
washes with PBS, 2 minutes each, cells were incubated 
with appropriate antibodies for two hours. The primary 
antibodies were washed off in PBS and cells incubated 
Table 1: Primers
Gene Forward sequence Reverse sequence
hPAR-1 AGGCCAGAATCAAAAGCAAC TCATCCTCCCAAAATGGTTC
hITGAV TCTGTGCCGCGCCTTCAACC AACATCCGGGAAGACGCGCTG
hITGB6 AAGTTGAGACCAGGTGGTGCGC CCATGGAGGCGGAGAGGTCCAT
Oncotarget65481www.impactjournals.com/oncotarget
with 1:100 dilution of secondary antibodies, FITC- or 
PE-conjugated (Alexa Fluor 488 and Alexa Fluor 555, 
Invitrogen, UK) for another two hours. Again, three 
washes were performed and the side walls of the chambers 
carefully removed. Coverslips were mounted onto each 
slide using three drops of mounting medium containing 
4,6-Diamidino-2-phenylindole (DAPI) which is a highly 
sensitive nucleic acid stain. Images were captured using 
confocal laser scanning microscopy Zeiss 700. Secondary 
antibody alone was used to correct for non-specific 
background.
Migration study
A549 cells were seeded in 96-well plates and 
allowed to form a confluent monolayer for 24 hours. 
Homogenous scratch wounds were introduced using 
a WoundMaker (Essen Bioscience, UK). The wound 
closure was monitored for up to 24 hours and data 
analysed using Incucyte Zoom Live Cell Imaging 
System (Essen Bioscience, UK). Two metric parameters 
were analysed: wound confluence, which reports the 
confluence of cells within the wound region, given as the 
percentage of the wound region area occupied by cells; 
and relative wound density, which relies on measuring 
the spatial cell density in the wound area relative to the 
spatial cell density outside of the wound area at a given 
time point.
Statistical analysis
All data in the figures are presented as mean 
values ± SEM and all experiments have been repeated 
independently at least twice with 3-6 technical replicates. 
Statistical analysis was performed between two treatment 
groups by unpaired Student’s t-test, and between multiple 
treatment groups by one-way analysis of variance 
(ANOVA) with Tukey post-hoc testing or two-way 
ANOVA with Bonferroni post-hoc test, using Graphpad 
Prism 5 software. The mean values of various parameters 
were considered to be significantly different when the p 
value was calculated to be less than 0.05.
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